Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.93
+0.07 (0.71%)
Mar 9, 2026, 2:41 PM EDT - Market open
Immatics Employees
Immatics had 682 employees as of December 31, 2024. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$87,861
Profits / Employee
-$357,601
Market Cap
1.33B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 165 |
| Monte Rosa Therapeutics | 147 |
| MoonLake Immunotherapeutics | 130 |
| Zenas BioPharma | 130 |
| ORIC Pharmaceuticals | 106 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
| AtaiBeckley | 54 |
IMTX News
- 1 hour ago - Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot - Seeking Alpha
- 2 months ago - Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
- 3 months ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 3 months ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 4 months ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 4 months ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 5 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 5 months ago - Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 - Seeking Alpha